Literature DB >> 16134145

Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.

Leonarda Ianzano1, Junjun Zhang, Elayne M Chan, Xiao-Chu Zhao, Hannes Lohi, Stephen W Scherer, Berge A Minassian.   

Abstract

Progressive Myoclonus Epilepsy (PME) of the Lafora type is an autosomal recessive disease, which presents in teenage years with myoclonia and generalized seizures leading to death within a decade of onset. It is characterized by pathognomonic inclusions, Lafora bodies (LB), in neurons and other cell types. Two genes causing Lafora disease (LD), EPM2A on chromosome 6q24 and NHLRC1 (EPM2B) on chromosome 6p22.3 have been identified, and our recent results indicate there is at least one other gene causing the disease. The EPM2A gene product, laforin, is a protein tyrosine phosphatase (PTP) with a carbohydrate-binding domain (CBD) in the N-terminus. NHLRC1 encodes a protein named malin, containing a zinc finger of the RING type in the N-terminal half and 6 NHL-repeat domains in the C-terminal direction. To date 43 different variations in EPM2A and 23 in NHLRC1 are known, including missense, nonsense, frameshift, and deletions. We have developed a human LD mutation database using a new generic biological database cross-referencing platform. The database, which currently contains 66 entries is accessible on the World Wide Web (http://projects.tcag.ca/lafora). Entries can be submitted via the curator of the database or via a web-based form. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16134145     DOI: 10.1002/humu.9376

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  22 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 2.  Lafora disease, seizures and sugars.

Authors:  D M Andrade; J Turnbull; B A Minassian
Journal:  Acta Myol       Date:  2007-07

3.  A novel mouse model that recapitulates adult-onset glycogenosis type 4.

Authors:  H Orhan Akman; Valentina Emmanuele; Yasemin Gülcan Kurt; Bülent Kurt; Tatiana Sheiko; Salvatore DiMauro; William J Craigen
Journal:  Hum Mol Genet       Date:  2015-09-18       Impact factor: 6.150

4.  Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.

Authors:  P S Srikumar; K Rohini; Perumbilavil Kaithamanakallam Rajesh
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

5.  Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.

Authors:  Vincent S Tagliabracci; Jean Marie Girard; Dyann Segvich; Catalina Meyer; Julie Turnbull; Xiaochu Zhao; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

Review 6.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

7.  Lafora disease as a cause of visually exacerbated myoclonic attacks in a dog.

Authors:  Aubrey A Webb; Chantal McMillan; Cheryl L Cullen; Sarah E Boston; Julie Turnbull; Berge A Minassian
Journal:  Can Vet J       Date:  2009-09       Impact factor: 1.008

8.  Efficacy and tolerability of perampanel in ten patients with Lafora disease.

Authors:  Danielle Goldsmith; Berge A Minassian
Journal:  Epilepsy Behav       Date:  2016-07-25       Impact factor: 2.937

9.  Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).

Authors:  Carolyn A Worby; Matthew S Gentry; Jack E Dixon
Journal:  J Biol Chem       Date:  2007-12-10       Impact factor: 5.157

10.  Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.

Authors:  Sudheendra N R Rao; Jaiprakash Sharma; Ranjan Maity; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2009-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.